WONDFO BIOTECH(300482) 海通国际·2025-05-15 11:00Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 24.18, compared to the current price of RMB 20.89 [1][9]. Core Insights - The company is exploring growth drivers across four major business areas, with a focus on chronic disease management and dual platforms. The revenue for infectious disease testing is projected to be RMB 1.04 billion in 2024, reflecting a growth of 9.50%. The chronic disease management segment is expected to generate RMB 1.37 billion, a significant increase of 22.38% [10][12]. - The report highlights breakthroughs in luminescence, molecular diagnostics, and pathology fields, with new products and technologies being introduced to enhance market competitiveness [11][12]. - The company has established a robust international sales team, exporting products to over 150 countries, which has contributed to rapid growth in non-U.S. overseas markets [12]. Financial Summary - For 2024, the company is expected to achieve a revenue of RMB 3.07 billion, representing a year-on-year increase of 10.85%. The net profit attributable to shareholders is forecasted at RMB 562 million, up 15.18% [3][9]. - The earnings per share (EPS) estimates have been adjusted to RMB 1.34 for 2025 and RMB 1.57 for 2026, with a new forecast of RMB 1.82 for 2027 [9][10]. - The financial metrics indicate a net profit margin improvement, with the net profit expected to grow steadily over the next few years [3][9].